Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM.

J Clin Oncol. 2018 May 20;36(15):1498-1504. doi: 10.1200/JCO.2017.76.4126. Epub 2018 Apr 6.

PMID:
29624463
2.

The effect of digital rectal exam on the 4Kscore for aggressive prostate cancer.

Maccini MA, Westfall NJ, Van Bokhoven A, Lucia MS, Poage W, Maroni PD, Wilson SS, Glodé LM, Arangua P, Newmark J, Steiner M, Werahera PN, Crawford ED.

Prostate. 2018 May;78(7):506-511. doi: 10.1002/pros.23495. Epub 2018 Feb 19.

PMID:
29460452
3.

Man With Locally Advanced, High-Risk Prostate Cancer Asks About Adding Chemotherapy to His Treatment.

Bourlon MT, Mora M, Hinojosa-Fano J, Martínez-Benitez B, Amini A, Castillejos-Molina R, Glodé LM.

Oncology (Williston Park). 2016 Jan;30(1):94-8. No abstract available.

4.

Progress in Prostate Cancer (at Last!).

Glodé LM.

Oncology (Williston Park). 2015 Jun;29(6):407, 414. No abstract available.

5.

Inhibition of Lipid Oxidation Increases Glucose Metabolism and Enhances 2-Deoxy-2-[(18)F]Fluoro-D-Glucose Uptake in Prostate Cancer Mouse Xenografts.

Schlaepfer IR, Glodé LM, Hitz CA, Pac CT, Boyle KE, Maroni P, Deep G, Agarwal R, Lucia SM, Cramer SD, Serkova NJ, Eckel RH.

Mol Imaging Biol. 2015 Aug;17(4):529-38. doi: 10.1007/s11307-014-0814-4.

6.

Base of the skull metastases in metastatic castration-resistant prostate cancer.

Bourlon MT, Glodé LM, Crawford ED.

Oncology (Williston Park). 2014 Dec;28(12):1115-6, 1124. No abstract available.

7.

Lipid catabolism via CPT1 as a therapeutic target for prostate cancer.

Schlaepfer IR, Rider L, Rodrigues LU, Gijón MA, Pac CT, Romero L, Cimic A, Sirintrapun SJ, Glodé LM, Eckel RH, Cramer SD.

Mol Cancer Ther. 2014 Oct;13(10):2361-71. doi: 10.1158/1535-7163.MCT-14-0183. Epub 2014 Aug 13.

8.

Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.

Lam ET, Glodé LM.

Hematol Oncol Clin North Am. 2013 Dec;27(6):1189-204, viii. doi: 10.1016/j.hoc.2013.08.004. Epub 2013 Sep 21. Review.

PMID:
24188258
9.

Nonseminomatous germ cell tumor of testis and interrupted treatment.

Glodé LM, Lam E.

Oncology (Williston Park). 2013 Aug;27(8):822-3. No abstract available.

10.

Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.

Beer TM, Schellhammer PF, Corman JM, Glodé LM, Hall SJ, Whitmore JB, Frohlich MW, Penson DF.

Urology. 2013 Aug;82(2):410-5. doi: 10.1016/j.urology.2013.04.049.

PMID:
23896100
11.

Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer.

Dorff TB, Glode LM.

Curr Opin Urol. 2013 Jul;23(4):366-71. doi: 10.1097/MOU.0b013e328361d467. Review.

12.

Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.

Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glodé LM, Flaig TW.

Clin Cancer Res. 2013 Jan 1;19(1):148-57. doi: 10.1158/1078-0432.CCR-12-1258. Epub 2012 Nov 21.

13.

Trends in twitter use by physicians at the american society of clinical oncology annual meeting, 2010 and 2011.

Chaudhry A, Glodé LM, Gillman M, Miller RS.

J Oncol Pract. 2012 May;8(3):173-8. doi: 10.1200/JOP.2011.000483. Epub 2012 Apr 17.

14.

Proliferative tumor doubling times of prostatic carcinoma.

Werahera PN, Glode LM, La Rosa FG, Lucia MS, Crawford ED, Easterday K, Sullivan HT, Sidhu RS, Genova E, Hedlund T.

Prostate Cancer. 2011;2011:301850. doi: 10.1155/2011/301850. Epub 2011 Sep 21.

15.

A rare case of metastatic renal epithelioid angiomyolipoma.

Lam ET, La Rosa FG, Suby-Long TD, Kondo KL, Wilson S, Glodé LM, Flaig TW.

Oncology (Williston Park). 2011 Aug;25(9):832-8. No abstract available.

16.

Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.

Clemons J, Glodé LM, Gao D, Flaig TW.

Urol Oncol. 2013 Feb;31(2):198-204. doi: 10.1016/j.urolonc.2010.12.004. Epub 2011 Jul 27.

17.

Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.

Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, Schellhammer PF, Jones LA, Xu Y, Kylstra JW, Frohlich MW.

Clin Cancer Res. 2011 Jul 1;17(13):4558-67. doi: 10.1158/1078-0432.CCR-10-3223. Epub 2011 May 10.

18.

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.

Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM.

J Clin Oncol. 2011 May 20;29(15):2040-5. doi: 10.1200/JCO.2010.32.2776. Epub 2011 Apr 18.

19.

Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer.

Amato RJ, Glode LM, Podolnick J, Knight R, Crawford D.

Cancers (Basel). 2011 Sep 2;3(3):3449-60. doi: 10.3390/cancers3033449.

20.

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR.

J Clin Oncol. 2010 Mar 1;28(7):1099-105. doi: 10.1200/JCO.2009.25.0597. Epub 2010 Jan 25.

21.

Management of the side effects of androgen deprivation therapy in men with prostate cancer.

Flaig TW, Glodé LM.

Expert Opin Pharmacother. 2008 Nov;9(16):2829-41. doi: 10.1517/14656566.9.16.2829 . Review.

PMID:
18937615
22.

Metabolic syndrome and prostate cancer.

Glode LM.

Cancer. 2008 May 15;112(10):2103-5. doi: 10.1002/cncr.23511. No abstract available.

23.

Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.

Flaig TW, Tangen CM, Hussain MH, Stadler WM, Raghavan D, Crawford ED, Glodé LM; Southwest Oncology Group.

J Clin Oncol. 2008 Mar 20;26(9):1532-6. doi: 10.1200/JCO.2007.13.4197.

PMID:
18349405
24.

Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice.

Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, Glode LM, Agarwal R.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3248-55.

25.

Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.

Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glodé LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R.

Cancer Res. 2007 Nov 15;67(22):11083-91.

26.

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.

Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC; National Cancer Institute.

J Clin Oncol. 2007 Jun 1;25(16):2218-24. Erratum in: J Clin Oncol. 2008 Jul 1;26(19): 3295.

PMID:
17538166
27.

Prostate cancer in a man with multiple previous cancers.

Flaig T, Crawford ED, Kavanagh B, Lucia S, La Rosa F, Barqawi A, Crighton F, Glodé LM.

Oncology (Williston Park). 2007 Apr;21(5):611-4. No abstract available.

28.

Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes.

Flaig TW, Nordeen SK, Lucia MS, Harrison GS, Glodé LM.

J Urol. 2007 Apr;177(4):1229-37. Review.

PMID:
17382696
29.

Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells.

Flaig TW, Su LJ, Harrison G, Agarwal R, Glodé LM.

Int J Cancer. 2007 May 1;120(9):2028-33.

30.

The effect of ultrasonic irradiation on doxorubicin-induced cytotoxicity in three human bladder cancer cell lines.

Arthur C, Flaig T, Su LJ, Denney R, Barnes F, Glodé LM.

Ultrasonics. 2007 Mar;46(1):68-73. Epub 2006 Nov 27.

PMID:
17173946
31.

The case for adjuvant therapy for prostate cancer.

Glodé LM.

J Urol. 2006 Dec;176(6 Pt 2):S30-3. Review.

PMID:
17084163
32.

A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.

Flaig TW, Gustafson DL, Su LJ, Zirrolli JA, Crighton F, Harrison GS, Pierson AS, Agarwal R, Glodé LM.

Invest New Drugs. 2007 Apr;25(2):139-46. Epub 2006 Nov 1.

PMID:
17077998
33.

New approaches to the treatment of advanced prostate cancer.

Goluboff ET, Hirano D, Thrasher JB, Stark G, Miller GJ, Glodé LM.

Rev Urol. 2001;3 Suppl 2:S69-78.

34.

Prostate cancer pathology, screening, and epidemiology.

Crawford ED, Miller GJ, Labrie F, Hirano D, Batuello J, Glodé LM.

Rev Urol. 2001;3 Suppl 2:S2-S10.

35.

Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma.

Denberg TD, Glodé LM, Steiner JF, Crawford ED, Hoffman RM.

BJU Int. 2006 Aug;98(2):335-40.

36.

A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer.

Flaig TW, Barqawi A, Miller G, Kane M, Zeng C, Crawford ED, Glodé LM.

Cancer. 2006 Jul 15;107(2):266-74.

37.

Gonadotropin-releasing hormone and its receptor in normal and malignant cells.

Harrison GS, Wierman ME, Nett TM, Glode LM.

Endocr Relat Cancer. 2004 Dec;11(4):725-48. Review.

38.

A comprehensive characterization of the peptide and protein constituents of human seminal fluid.

Fung KY, Glode LM, Green S, Duncan MW.

Prostate. 2004 Oct 1;61(2):171-81.

PMID:
15305340
39.

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.

Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED.

Prostate. 2004 Sep 1;60(4):332-7.

PMID:
15264245
40.
41.

High Gleason scores and lower prostate-specific antigen levels in a single institution over the past decade.

Abouelfadel Z, Miller GJ, Glode LM, Akduman B, Donohue RE, Nedrow A, Crawford ED.

Clin Prostate Cancer. 2002 Sep;1(2):115-7.

PMID:
15046702
42.

Prostate cancer on the internet: impact on patients and how technology helps physicians and researchers.

Bergen M, Lewis K, Chen R, Kenney T, Glode LM.

Clin Prostate Cancer. 2003 Mar;1(4):227-34.

PMID:
15040881
43.

Binding and cytotoxicity of conjugated and recombinant fusion proteins targeted to the gonadotropin-releasing hormone receptor.

Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA, Crawford ED, Glode LM.

Cancer Res. 2004 Mar 15;64(6):2090-5.

44.

Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors.

Qi L, Robinson WA, Brady BM, Glode LM.

Anticancer Res. 2003 Sep-Oct;23(5A):3917-22.

PMID:
14666697
45.

Silibinin down-regulates survivin protein and mRNA expression and causes caspases activation and apoptosis in human bladder transitional-cell papilloma RT4 cells.

Tyagi AK, Agarwal C, Singh RP, Shroyer KR, Glode LM, Agarwal R.

Biochem Biophys Res Commun. 2003 Dec 26;312(4):1178-84.

PMID:
14651997
46.

Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line.

Qi L, Singh RP, Lu Y, Agarwal R, Harrison GS, Franzusoff A, Glode LM.

Cancer Biol Ther. 2003 Sep-Oct;2(5):526-31.

PMID:
14614320
47.

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma.

Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R.

Cancer. 2003 Oct 15;98(8):1643-8.

48.

GnRH-PAP hormonotoxin targets cytotoxicity to prostate cancer cell lines.

Qi L, Nett TM, Allen MC, Sha X, Harrison GS, Frederick BA, Glode LM.

Urol Res. 2003 Dec;31(6):374-7. Epub 2003 Sep 13.

PMID:
13680022
49.
50.

High-risk localized prostate cancer: primary surgery and adjuvant therapy.

Skinner EC, Glode LM.

Urol Oncol. 2003 May-Jun;21(3):219-27. Review.

PMID:
12810210

Supplemental Content

Loading ...
Support Center